TW200518788A - Extended release pharmaceutical dosage form - Google Patents

Extended release pharmaceutical dosage form

Info

Publication number
TW200518788A
TW200518788A TW093130742A TW93130742A TW200518788A TW 200518788 A TW200518788 A TW 200518788A TW 093130742 A TW093130742 A TW 093130742A TW 93130742 A TW93130742 A TW 93130742A TW 200518788 A TW200518788 A TW 200518788A
Authority
TW
Taiwan
Prior art keywords
extended release
venlafaxine
dosage forms
release pharmaceutical
pharmaceutical dosage
Prior art date
Application number
TW093130742A
Other languages
English (en)
Inventor
Nicholas Heaton
Angela Potts
Ian Armstrong
James Andrew Provost
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34354596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200518788(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200518788A publication Critical patent/TW200518788A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093130742A 2003-10-13 2004-10-11 Extended release pharmaceutical dosage form TW200518788A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03256438A EP1523979A1 (en) 2003-10-13 2003-10-13 Extended release pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
TW200518788A true TW200518788A (en) 2005-06-16

Family

ID=34354596

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093130742A TW200518788A (en) 2003-10-13 2004-10-11 Extended release pharmaceutical dosage form

Country Status (14)

Country Link
US (1) US20050129762A1 (zh)
EP (2) EP1523979A1 (zh)
KR (1) KR20060108675A (zh)
CN (1) CN1889935A (zh)
AR (1) AR046102A1 (zh)
AU (1) AU2004283436A1 (zh)
CA (1) CA2546199A1 (zh)
CO (1) CO5690532A2 (zh)
CR (1) CR8403A (zh)
EC (1) ECSP066566A (zh)
NO (1) NO20062142L (zh)
PE (1) PE20050439A1 (zh)
TW (1) TW200518788A (zh)
WO (1) WO2005039527A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP2114455A4 (en) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc PHARMACEUTICAL COMPOSITION USING A HOT-MELT GRANULATED AGENT
AU2014201170B2 (en) * 2006-12-20 2015-09-24 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
US8142803B2 (en) 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
CN113143901A (zh) 2007-03-22 2021-07-23 纽罗森特里亚股份有限公司 镁组合物及其用途
CN102573496B (zh) * 2009-07-01 2015-08-26 玛格塞蒂克斯公司 缓释镁组合物及其用途
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556141A (zh) * 1956-03-27
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
AU2003226748A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Compositions of venlafaxine base
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
AU2003249492A1 (en) * 2003-07-24 2005-02-14 Eswaran Krishnan Iyer Oral compositions for treatment of diseases

Also Published As

Publication number Publication date
NO20062142L (no) 2006-07-06
EP1675575A2 (en) 2006-07-05
WO2005039527A2 (en) 2005-05-06
CO5690532A2 (es) 2006-10-31
CR8403A (es) 2006-10-26
AU2004283436A1 (en) 2005-05-06
KR20060108675A (ko) 2006-10-18
EP1523979A1 (en) 2005-04-20
WO2005039527A3 (en) 2006-04-06
AR046102A1 (es) 2005-11-23
PE20050439A1 (es) 2005-08-03
ECSP066566A (es) 2006-10-17
CA2546199A1 (en) 2005-05-06
CN1889935A (zh) 2007-01-03
US20050129762A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
ECSP066566A (es) Formas de dosificación farmacéutica de liberación extendida
IL198985A0 (en) Crystalline solid rasagiline base
WO2006058059A3 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
HK1129581A1 (zh)
CA2449729A1 (en) Prodrugs of gaba analogs, compositions and uses thereof
IL196627A (en) Preparation of (r2, r3) –3– (3– methoxyphenyl) - n, n, 2– trimethylphentanamine
HK1091137A1 (en) Extended release coated minitablets of venlafaxinehydrochloride
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
GEP20105052B (en) Alcohol resistant dosage forms
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
MY146405A (en) Fast-release microcapsule products
WO2008064202A3 (en) Modified-release formulations of calcium receptor-active compounds
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
NO20062143L (no) Tablettformuleringer av venlafaxin med forlenget frigjoring
WO2007110709A3 (en) Formulations of tipifarnib for intravenous administration
MX2007014963A (es) Composicion de liberacion modificada de al menos una forma de venlafaxina.
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
MX339136B (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla.
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2003086362A3 (en) Method of stabilizing bupropion hydrochloride tablets
WO2008142896A1 (ja) パップ剤及びパップ剤の製造方法
MX2009005804A (es) Composicion farmaceutica de memantina.
UA87474C2 (ru) Способ получения 6-амино-4-(3-хлоро-4-фторофениламино) )-7-этоксихинолин-3-карбонитрила, промежуточные соединения и способ получения промежуточного соединения
WO2008111296A1 (ja) 角化の亢進に起因する皮膚疾患の予防及び治療のための医薬